DCZ0415 |
Katalog-Nr.GC39370 |
DCZ0415, ein potenter TRIP13-Inhibitor, beeintrÄchtigt die nicht-homologe Endverbindungsreparatur und hemmt die NF-κB-AktivitÄt. DCZ0415 induziert Anti-Myelom-AktivitÄt in vitro, in vivo und in PrimÄrzellen, die von arzneimittelresistenten Myelompatienten stammen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2242470-43-3
Sample solution is provided at 25 µL, 10mM.
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].
[1]. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *